Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TraPPer: Pertuzumab, Trastuzumab, Hyaluronidase-zzxf Plus Enzalutamide in mCRPC
NCT05730712Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2024
- Primary completion
- Apr 2025
- Modality
- Therapeutic Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab + trastuzumab + hyaluronidase-zzxf in castration-resistant prostate cancer (CRPC), sponsored by Mayo Clinic. Started Mar 2024; status: completed.
02
Drugs
pertuzumab + trastuzumab + hyaluronidase-zzxf
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05730712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730712.